A federal judge has scheduled a status conference for December 19 for parties involved in Paraquat Parkinson's disease litigation to discuss the next steps toward holding bellwether trials.
With the first Ozempic lawsuit bellwether trials not expected to begin until at least late 2026 or early 2027, the court will address motions to dismiss and other “cross cutting” issues in 2025.
The first Valsartan bellwether trial will begin on September 8, 2025, involving allegations that the generic hypertension drug contained toxic chemicals that resulted in a liver cancer diagnosis.
